BIM
PRTK

Bogle Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bogle Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,619
Closed -$517K – 376
2017
Q3 		$517K Buy
+20,619
New +$480K 0.04% 258
2017
Q2 		– Sell
-33,183
Closed -$638K – 395
2017
Q1 		$638K Buy
+33,183
New +$523K 0.04% 254
2016
Q4 		– Sell
-21,937
Closed -$285K – 424
2016
Q3 		$285K Buy
+21,937
New +$291K 0.02% 325

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Bogle Investment Management's PRTK Position: Q4 2017 in Review

Bogle Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 20,619 shares — an estimated $517K sold.

Bogle Investment Management first reported a position in PRTK in Q3 2016 and held it in 3 quarters. The position peaked at $638K in Q1 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Bogle Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Bogle Investment Management sold 20,619 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $517K.
  • Bogle Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Bogle Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $638K in Q1 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Bogle Investment Management's 13F filing for Q4 2017, filed 13 Feb 2018.